• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Almirall Inc.

    企业
    431论文总数
    8,502引用总数

    Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.In 2016, it generated total revenue of €859.3 million and became the leading pharmaceutical company in R&D investment in Spain.With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and United States.

    论文量&引用量时间轴

    机构学者

    论文(431)

    年份
    起
    –
    止
    排序
    1Patient- and Clinician-Reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study)
    Y Gilaberte, O Yélamos, J Cañueto, C Serra-Guillén, A Conti, F Pajuelo, A Lecchi, V Cappello, B Kostov, L Padullés, M Romanelli

    OBJECTIVE:To assess patient- and clinician-reported outcomes, efficacy, and safety of tirbanibulin 1% administered to patients with actinic keratoses (AKs) in Spain and Italy. METHODS:TIRBASKIN is a multicenter, single-cohort, phase IV, low-interventional clinical study conducted among adults with 4-8 AK lesions on the face or scalp in an area ≤25cm2. Patients applied tirbanibulin for 5 consecutive days. The primary endpoint was treatment satisfaction on day 57 (D57), assessed with the Treatment Satisfaction Questionnaire for Medication 9 (TSQM-9). Efficacy was assessed by the percentage of patients with complete clearance (CC) and partial clearance (PC) at D57. Tolerability was assessed by local tolerability signs (LTSs), also known as local skin reactions. RESULTS:A total of 328 patients (mean age, 74.8 years; male, 83.5%; Fitzpatrick skin type II, 53.7%; AKs on the scalp, 52.7%) completed study assessments at D57. Patients reported high levels of satisfaction with tirbanibulin as assessed by TSQM-9 (effectiveness mean score, 73.6; convenience mean score, 82.8; global satisfaction mean score, 76.9). Moreover, 87.7% of clinicians and 81.8% of patients reported overall satisfaction with tirbanibulin as much/somewhat better compared with previous topical treatment. In addition, 87.1% of clinicians and 86.3% of patients reported a likelihood of reconsidering tirbanibulin in the future, if needed. CC was achieved by 54.3% of patients and PC by 76.2%. At D8, the most frequent LTSs were erythema/redness (mild/moderate, 72.2%; severe, 2.2%) and flaking/scaling (mild/moderate, 34.6%; severe, 0.6%), which had mostly resolved by D57. CONCLUSIONS:Patients' and clinicians' satisfaction was high, and both groups reported a high likelihood of using tirbanibulin again, if needed.

    2026Actas dermo-sifiliograficas(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2A Phase 3 Study Assessing the Efficacy, Safety and Tolerability of Up to Two 5-Day Treatment Courses of Tirbanibulin 1% Ointment in Patients with Actinic Keratosis (AK) over a Treatment Field Up to Approximately 100 Cm2
    Julia Welzel,Jacek C. Szepietowski,Carla Ferrandiz Pulido,Giovanni Pellacani,Klara Mosterd,Raquel Otero, Ana Maria Perez Fierro, Lucio Malvisi, Hilary Siddall,Ignasi Pau-Charles,Thomas Dirschka
    2026JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    3Efficacy, Safety and Willingness to Be Retreated with Tirbanibulin 1% Ointment in Patients with Actinic Keratosis over a Field Treatment Up to 100 Cm²
    J. Welzel, J.C. Szepietowski, C. Ferrándiz-Pulido, G. Pellacani, K. Mosterd, R. Otero, A.M. Pérez Fierro, L. Malvisi, H. Siddall, G. Denton, L. Padullés, I. Pau-Charles,
    2026EJC Skin Cancer(2026)
    引用
    AI阅读
    加入学术空间
    4Achieving Complete Clearance (CC) in Actinic Keratosis (AK) after Treatment with Tirbanibulin 1% with Mild to Moderate Local Skin Reactions (lsrs): a Pooled Post-Hoc Analysis of Three Phase III Studies
    Edward (Ted) Lain,Naiem T. Issa,Vishal Patel,Todd Schlesinger,C. William Hanke,Martin Zaiac, Francisco Hernandez Vicente,Laura Padulles,Raidah Salem,Paul Tomondy,Neal Bhatia
    2026JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    5Patients Maintain Stable Response with No or Minimal Fluctuations During 3 Years of Continuous Treatment with Lebrikizumab During Long-Term Extension Trial
    Jonathan Silverberg,Linda Stein Gold, Peter Lio,James del Rosso,Andreas Wollenberg,Jose-Manuel Carrascosa,Gaia Gallo, Yuxin Ding, Helena Agell, Sebastian Diemert,Christian Vestergaard
    2026JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 431 篇论文

    合作机构(100)

    巴塞罗那大学合作论文 25
    礼来公司合作论文 14
    乔治华盛顿大学合作论文 12
    西奈山伊坎医学院合作论文 12
    瓦伦西亚大学合作论文 11
    Hospital Universitario Miguel Servet合作论文 10
    迈阿密大学合作论文 9
    巴塞罗那自治大学合作论文 9
    Therapeutics Clinical Research合作论文 9
    伦敦大学合作论文 9

    机构统计